CN1384207A

CN1384207A - Ovarian cancer detection method and kit

Info

Publication number: CN1384207A
Application number: CN 01117606
Authority: CN
Inventors: 关新元
Original assignee: Cen Xintang
Current assignee: Cen Xintang
Priority date: 2001-04-30
Filing date: 2001-04-30
Publication date: 2002-12-11
Anticipated expiration: 2021-04-30
Also published as: CN1252283C

Abstract

The present invention provides a method for detecting human chromosomal abnormalities (particularly 3q26.2 abnormalities) for genetic diagnosis and prognosis of cancer, comprising the steps of contacting a chromosomal sample from a subject with a composition comprising one or more nucleic acid probes under conditions such that a stable hybridization complex is formed between the probe and a target sequence, wherein the probe comprises a nucleotide sequence of full-length eIF-5 a2 or a fragment thereof, and detecting the hybridization complex. The invention also provides a corresponding detection kit.

Description

The detection method of ovarian cancer and test kit

The present invention relates to the cytogenetics field.More specifically, the present invention relates to differentiate that eukaryotic initiation suppresses the amplification of 5A2 (eIF-5A2), this amplification is the good diagnostic indicator of multiple cancer.In addition, the present invention also provides probe and the test kit special to eIF-5A2.

Ovarian cancer is the cause of disease that causes death main in women's urogenital cancer, and about 1% American Women is subjected to the influence of ovarian cancer in life at it.If not by early diagnosis, the prognosis of ovarian cancer is very poor, and five year survival rate is less than 10%.Compare with some other solid tumor, people understand very few to the molecular pathogenesis and the evolution thereof of ovarian cancer so far.

Chromosome abnormalty is relevant with genetic diseases, degenerative disorders and cancer usually.Particularly, the disappearance of whole karyomit(e) or chromosomal fragment copy or duplicate, and the more high-grade amplification of genome specific region betide in the cancer usually.In fact, containing the amplification of dna sequence dna of proto-oncogene and tumor suppressor gene and disappearance, often to be that tumour takes place peculiar.Clearly, to the evaluation in amplification and disappearance zone and to the clone of genes involved, take place and the exploitation cancer diagnosis technology all is vital for the research tumour.

Detect the chromosomal region of amplification or disappearance, undertaken by cytogenetics usually.Because DNA forms karyomit(e) through complex folds, so the resolving power of cytogenetics technology is limited to the zone greater than about 10MB; This almost is the width of band in the painted karyomit(e) of Giemsa.The purposes of conventional cell genetic analysis method is very limited in the caryogram that a plurality of swivel bases of having of complexity and other heredity changes, in default of caryogram information or be difficult to be explained.Conventional in addition cytogenetics strip analysis method wastes time and energy, and often very difficult or impossible.

Recently, clone's probe has been used for assessing the quantity of given dna sequence dna at karyomit(e) by the Southern blotting.Even at genome is highly to reset, so that eliminate under the situation of useful caryogram information, this method also is effective.Yet the Southern blotting has only provided any information that the roughly estimation of relative dna sequence copy numbers can not provide this sequence position in karyomit(e).

Relatively karyomit(e) hybrid method (CGH) is that upgrade a kind of differentiates that whether amplification/deletion sequence exists and the method for position.The same with the Southern blotting, CGH can disclose amplification and disappearance, and is not subjected to the influence of genome rearrangement.In addition, CGH provides than the more quantitative estimation to copy number of Southern blotting, but also amplification or the positional information of deletion sequence in the normal dyeing body can be provided.

Recently, with comparative genome hybridization technology (CGH), in primary carcinoma of ovary, identified the zone of a frequent amplification among the 3q25-qter.Minimum overlapping amplification region is located in 3q26.

Identifying corresponding oncogene in the chromosomal region of frequent amplification and the described zone, is indispensable for understanding tumorigenic molecule mechanism.Recently, the PIK3CA of the catalytic subunit of coding phosphatidyl-inositol 3-kinase has been the candidate oncogene (Shayesteh, L., et al., Nat.Genet., 21:99-102,1999) in 3q26 district by hint.Because low-level PIK3CA amplification is only arranged in some cases, and ovarian cancer cell line UACC-1598 contains the amplification (Brooks of high-caliber double minute form in the 3q26 district, D.J., etal., Br.J.Cancer, 74:1518-1525,1996), so may also have another oncogene in this zone.

Therefore, this area presses for and seeks and the Cancer-Related oncogene of ovary, the especially oncogene in the 3q26 district.Yet, before the application, also do not report and confirmed other and the Cancer-Related oncogene of ovary.

In a first aspect of the present invention, a kind of unusual method of human chromosome that detects is provided, it comprises step:

Can form under the condition of stablizing hybridization complex at probe and target sequence, the karyomit(e) sample of object to be measured is contacted with the composition that contains one or more nucleic acid probes, wherein said probe contains total length eIF-5A2 or its segmental nucleotide sequence; With

Detect described hybridization complex.

Preferably, the step of described detection hybridization complex comprises the copy number that detects target sequence.

In an example of the present invention, described detection hybridization complex is by detecting fluorescent marker.

In an example of the present invention, described chromosome abnormalty is amplification.

5. the method for claim 1, described total length eIF-5A2 and fragment thereof comprise: DNA, cDNA and antisense DNA.

In another aspect of this invention, provide a kind of test kit that detects cancer, it comprises:

The nucleic acid probe of mark, this probe can be incorporated into the nucleotide sequence of people eIF-5A2 specifically, and this nucleic acid contains total length eIF-5A2 and segmental nucleotide sequence thereof.

Preferably, described test kit also contain to the telomeric sequence of karyomit(e) 3 special with reference to probe.

In another aspect of this invention, provide a kind of method that detects tumour or tumor susceptibility,

The probe that will contain total length eIF-5A2 or its segmental nucleotide sequence is hybridized with DNA of individual sample to be measured; With

Detect the heterozygote number that forms and whether be higher than normal control,

Wherein whether the heterozygote number of Xing Chenging is higher than normal control and just represents that this individuality suffers from tumour or tumor susceptibility is higher than normal population.

Preferably, described tumour is selected from down group: ovarian cancer, nasopharyngeal carcinoma, prostate cancer and carcinoma of fallopian tube.

In still another aspect of the invention, provide a kind of method that detects tumour or tumor susceptibility, it comprises step:

Under the condition that is fit to the formation antibody complex, will contain the proteic antibody of the anti-eIF-5A2 of specificity and contact with DNA of individual sample to be measured; With

Detect the antibody complex quantity that forms and whether be higher than normal control,

Wherein the antibody complex quantity of Xing Chenging is higher than normal control and just represents that this individuality suffers from tumour or tumor susceptibility is higher than normal population.

Fig. 1: A is with the amplification situation of the detected 3q25-q26 of CGH in two routine primarys carcinoma of ovary.Tumour DNA and normally marking with green and redness with reference to DNA.B is with the 3q26 DNA of micro-dissection and normal Metaphase Chromosome hybridization (shown part mid-term).C, the part mid-term of G-striping, the wherein hybridization at arrow points 3q26.2 place.D carries out FISH with the BAC clone (redness) who contains eIF-5A2 the part mid-term identical with Fig. 1 C then, is positioned at 3q26.2.

Fig. 2: the series arrangement of the people eIF-5A2 aminoacid sequence of derivation and people eIF-5A and chicken eIF-5A.Identical sequence marks with black.8-hydroxyl-2,7, the Minimum Area that 10-triamino capric acid (hppusine) is modified required eIF-5A marks with the frame line.Asterisk is modified to 8-hydroxyl-2,7 after being illustrated in translation, the lysine residue of 10-triamino capric acid.

Fig. 3: with Southern blotting (Fig. 3 A) with carry out PCR (Fig. 3 B) with the primer in the exon (204bp) and confirmed that the BAC clone contains the eIF-5A2 gene.Genomic dna prepares from normal placenta, and the BAC clone hybridizes with EcoRI digestion and with eIF-5A2 cDNA.Fig. 3 C detects the expression of eIF-5A2 in 6 kinds of healthy tissuess with RT-PCR.

Fig. 4: A, Southern blotting show that eIF-5A2 has amplification in 5 kinds of primarys carcinoma of ovary and ovarian cancer cell line UACC-1598.15mg is through the DNA of EcoRI digestion, in 0.8% sepharose, separate and with 1.2kb eIF-5A2 cDNA probe hybridization.Probe at beta-actin is used as contrast.

B is to the Northern engram analysis of 4 kinds of primarys carcinoma of ovary and UACC-1598.The total RNA of sample 10mg in each swimming lane, and with 1.2kb eIF-5A2 cDNA probe hybridization.For the Northern trace, in contrast with the RNA separating gel of ethidium bromide staining.

Fig. 5: in two ovarian cancer cell lines, increase with the detected eIF-5A2 of FISH.A, the BAC clone that will contain eIF-5A2 hybridizes with the double minute among the ovarian cancer cell line UACC-1598.B observes the eIF-5A2 of 6 copies in ovarian cancer cell line OVACA3.C, eIF-5A2 are located in the minimum overlapping amplification region among the 3q26.2.

In the inventor's CGH research, in 15/30 (50%) primary carcinoma of ovary, detect 3q amplification (gain).Observing the height copy amplification of 3q in the minimum district that overlaps among the 3q26 in 4 cases (OV-4, OV-7, OV-13 and OV27).The 3q amplification is also through being common in some other solid tumor, as nasopharyngeal carcinoma, prostate cancer and carcinoma of fallopian tube etc.These researchs show strongly, may contain with the morbidity of various solid tumors (comprising ovarian cancer) in the 3q26 district and develop relevant oncogene.

The inventor utilizes the dna sequence dna of eIF-5A2 to filter out a BAC clone (PP11-115J24) who carries eIF-5A2 from bacterial artificial chromosome (BAC) storehouse, and the application fluorescence in situ hybridization technique is located at No. 3 long-armed 3q26 bands of karyomit(e).By detecting, prove that eIF-5A2 has in various degree DNA cloning and RNA to cross high expression level in the ovarian cancer of the 3q26 band amplification that we detect with CGH with Southern trace and Northern engram technology.Particularly in a kind of ovarian cancer cell strain (UACC-1598) that has a double minute (DM), the BAC clone hybridization that has eIF-5A2 is to double minute.Double minute is a kind of extrachromosomal small pieces segment DNA, is considered to one of gene amplification performance on cytology in the tumour cell.UACC-1598 has been proved from 3q26 and has been with.So eIF-5A2 can be considered to one of topmost carcinogenic genes involved of this example ovarian cancer.

The clinical diagnosis and the prognosis inventor that the eIF-5A2 gene is used for malignant tumour utilize tissue array technology that nearly 200 routine primary carcinoma of ovary patients are carried out the eIF-5A2 augmentation detection, found that the prognosis of the amplification of eIF-5A2 and ovarian cancer is closely related.Be detected the patient of eIF-5A2 amplification, its 5 years survival rates are starkly lower than the patient that no eIF-5A2 increases.So whether eIF-5A2 increases and can be used as one of important indicator of judging ovarian cancer patient prognosis.In addition, because the 3q amplification is common in malignant tumours such as nasopharyngeal carcinoma, prostate cancer and esophagus cancer, so the eIF-5A2 amplification also can be used as one of foundation of these tumor prognosis.

Definition

As used herein, " karyomit(e) sample " refers to the tissue that is used for standard in situ hybridization or the cell sample that prepare.Each karyomit(e) remains intact and contains usually expansion (spread) and the interphasic nucleus of the metaphase of with good grounds standard technique preparation substantially in this sample of preparation.

" nucleic acid " refers to the deoxyribonucleotide or the ribonucleoside acid polymer of strand or double chain form.This term has comprised the analogue of the natural nucleotide that can play a role with the natural nucleotide similar fashion unless otherwise indicated.

" subsequence " refers to contain the nucleotide sequence of a part of nucleic acid in the longer sequencing nucleic acid.

" probe " or " nucleic acid probe " refers to the set of one or more nucleic acid fragments, can detect the hybridization of they and target.Probe is by mark as described below, makes to detect it and the combining of target.Probe is with the preparation of the genome of one or more specific parts, for example the complete karyomit(e) of one or more clone and separate or chromosomal fragment or polymerase chain reaction (PCR) product.Probe can be processed by some way, for example by sealing or remove multiple nucleic acid or being rich in unique nucleic acid.Therefore term " probe " not only refers to detectable nucleic acid, also refers to be applied to the detected nucleic acid of target.

" hybridization " refers to by the pairing of complementary base two single-chain nucleic acids be combined.

" be incorporated into substantially " or " specific combination " or " selective binding " or " specific hybrid in ", the complementary hybridization of finger between oligonucleotide and target sequence, and can comprise small mispairing, these mispairing can realize detecting required target polynucleotide sequence by the tight degree that reduces hybridization medium.This term also refers under stringent condition, a part in conjunction with, compound or hybridization and specific nucleotide sequence, when this sequence is present in the compound mixture (as total cell NDA or RNA).Term " stringent condition " refers to that probe hybridization decides subsequence in target and do not hybridize condition in other sequences.Stringent condition is sequence-dependent, and is different under different situations.Long sequence can be under higher temperature specific hybrid.Usually, Xuan Ding stringent condition is than low about 5 ℃ of the pyrolysis chain temperature (Tm) of inferring sequence under ionic strength that limits and pH.This Tm is when reaching balance, have an appointment 50% with the probe of target complement sequence the temperature (under ionic strength, pH and the nucleic acid concentration of qualification) during with target sequence hybridization.Usually, for short probe, stringent condition is such condition, and wherein salt concn is at least about 0.02Na ionic concn (or other salt), pH7.0-8.3, and temperature is at least about 60 ℃.Stringent condition also can be realized by adding destabilizing agent such as methane amide.

Person of skill in the art will appreciate that the definite sequence of concrete probe described herein can be revised (modifications) to a certain extent, to produce but reservation is incorporated into the probe of target sequence ability substantially with disclosed probe " basic identical ".These modifications are covered by each probe of this paper." basic identical " of term polynucleotide refers to, compares with canonical sequence, and a sequence has at least 90%, more preferably at least 95% sequence homogeny.

Two nucleotide sequences are considered to " identical ", if when arranging with maximum correspondence, the nucleotide sequence in two sequences is identical.As used herein, term " complementation " refer to complementary sequence and canonical sequence all or part of be sequence.

Sequence between two (or a plurality of) polynucleotide relatively, normally the sequence with two sequences compares in " comparison window " scope, to differentiate and the sequence homogeny of regional area relatively.As used herein, " comparison window " refers at least about 20 adjoining positions, and about usually 50-200 more generally is about 100-150 adjoining position, wherein after two sequences are by optimal arrangement, with a sequence with have the canonical sequence of similar number and compare in abutting connection with the site.

Determining of " sequence homogeny per-cent " is to compare in comparison window by the sequence with two optimal arrangement to draw.Wherein compare with canonical sequence (do not contain and insert or disappearance), in order to obtain the optimal arrangement of two sequences, the polynucleotide sequence in comparison window can contain insertion or disappearance (being breach).Being calculated as follows of per-cent:, obtain the number of matched position by determining the number of in two sequences identical nucleic acid base or amino-acid residue.Multiply by 100% then with the sum of matched position number, and with the result, thereby obtain sequence homogeny per-cent divided by position number in the comparison window.

Another kind shows that nucleotide sequence is essentially identical method, is to judge whether two molecules hybridize in same sequence under stringent condition.Stringent condition is sequence-dependent, and is different under different situations.

Person of skill in the art will appreciate that, use sequence information disclosed herein and clone, the technician can pass through ordinary method (as Southern or Northern blotting), separates same or analogous probe from people's gene group library.

The mark of probe

The method of labeling nucleic acid probe is well known to those skilled in the art.Preferred probes is the probe that is applicable in situ hybridization.Before hybridization, nucleic acid probe can be detected ground mark.Perhaps, use the detectable that is incorporated into the hybridization product.These detectable are well known in the art, and comprise any material with detectable physics or chemical property.

As used herein, " marker " is any material that detects by spectrography, photoelectric method, biochemical process, immuno-chemical method or chemical method.Can be used for marker of the present invention comprises: radioactively labelled substance (as ³²P, ¹²⁵I, ¹⁴C, ³H, ³⁵S), fluorescence dye (as fluorescein, rhodamine), electron dense reagent (as) gold, enzyme (as enzyme commonly used among the ELISA), colorimetric mark (as Radioactive colloidal gold), the magnetic mark is (as Dynabeads ^TM) etc.Directly do not detect but can pass through and use direct certification mark thing and detected marker example, comprise the haptens and the protein of vitamin H, digoxin and existing mark antiserum(antisera) or monoclonal antibody.

Use concrete marker unimportant for the present invention, as long as it does not disturb the dyeing of in situ hybridization.Yet for karyomit(e) hybridization, it is preferred carrying out substantive dyeing with fluorescent marker (as fluorescein-12-dUTP etc.).

As used herein, directly the probe of mark is the probe that is attached with detectable.Because directly marker is attached on the probe, therefore do not need step that probe and detectable are associated subsequently.In contrast, the probe of indirect labelling be carry subsequently (usually in probe and target nucleic acid hybridization back) can be in conjunction with the probe of the molecule of detectable.

In addition, probe should be able to detect alap copy number, thereby makes the sensitivity of analysis the highest, can be higher than background signal again simultaneously.At last, the probe of high local signal must be selection can provided, thereby when coloration result and karyomit(e) are carried out physical positioning, high spatial resolution can be provided,

Available the whole bag of tricks well known by persons skilled in the art is coupled to probe with marker.In preferred example, nucleic acid probe is with nick translation or random primer extension method mark.

It is definitely special to skilled person in the art will appreciate that probe of the present invention there is no need eIF-5A2.On the contrary, probe is used for producing " dyeing contrast "." contrast " is by determining at the genome target region middle probe concentration and the ratio of other regional middle probe concentration of genome.

As mentioned above, the amplification that detects eIF-5A2 is whether multiple cancer exists and the sign of prognosis.These cancers comprise (but being not limited to): ovarian cancer, nasopharyngeal carcinoma, prostate cancer and carcinoma of fallopian tube.

In a preferred embodiment, detect the amplification of eIF-5A2 by hybridization with probe of the present invention and target nucleic acid (as the karyomit(e) sample).Suitable hybridization mode is well known by persons skilled in the art, comprises (but being not limited to) various Southern blottings, in situ hybridization and quantitative amplification method (as quantitative PCR).

In a preference, the eIF-5A2 amplification is differentiated by in situ hybridization.Usually, in situ hybridization comprises following key step: (1) fixes tissue or biological structure to be analyzed; (2) biological structure is carried out the accessibility (acessibility) of prehybridization with the increase target DNA, and reduce non-specific binding; (3) nucleic acid in nucleic acid mixture and biological structure or the tissue is hybridized; (4) washing after hybridizing is to remove in hybridization the not nucleic acid of hybridization; (5) detect the nucleic acid fragment of hybridizing.According to concrete application, the reagent and the working conditions that are used for each step can change.

Be used to detect the FISH method of chromosome abnormalty, can be used for the related nucleic acid of nanogram quantity.Can use paraffin-embedded tumor biopsy, and fresh or refrigerated sample.Because FISH can be used for a limited number of materials, therefore can use the prepared contact goods of never cultivating of primary tumor (touch preparation).For example, can use from a small amount of biopsy samples of tumour with preparation contact goods.Can also analyze from the cell in a small amount of needle biopsy sample or the body fluid (as blood, urine etc.).For antenatal diagnosis, suitable sample comprises amniotic fluid etc.

In the Southern blotting, genome or cDNA (normally fragmentation is also used the electrophoresis gel separation) and the probe hybridization special to target region.Will be from hybridization signal intensity at the probe of target region, and compare, thereby the estimated value of the relative copy number of target nucleic acid is provided at multiple (nonamplifie) strength of signal as the probe of centromere DNA.

EIF-5A2 nucleic acid, albumen and antibody

Based on the dependency of disclosed eIF-5A2 and ovarian cancer and the sequence information of eIF-5A2, utilize the ordinary skill in the art to produce eIF-5A2 albumen or fragment, and produce the antibody of anti-eIF-5A2 with corresponding eIF-5A2 albumen or fragment.

People eIF-5A2 Nucleotide full length sequence of the present invention or its fragment can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.

In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.

In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.

At present, can be fully come the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced then in the various dna moleculars (as carrier) and cell in this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.

The proteic fragment of the present invention is except available recombination method produces, and also available solid phase technique is produced (people such as Stewart, (1969) Solid-Phase Peptide Synthesis, WHFreeman Co., San Francisco by direct peptide synthesis; Merrifield J. (1963) J.Am Chem.Soc 85:2149-2154).Can carry out by hand or automatically at external synthetic protein.For example, can (Foster City CA) synthesizes peptide automatically with the 431A type peptide synthesizer of AppliedBiosystems.Can distinguish proteic each fragment of chemosynthesis the present invention, be connected to produce the molecule of total length with chemical process then.

On the other hand, the present invention also comprises people eIF-5A2 DNA or the polypeptide of its fragment coding has specific polyclonal antibody and monoclonal antibody, especially monoclonal antibody.Here, " specificity " is meant that antibody capable is incorporated into people eIF-5A2 gene product or fragment.Preferably, refer to that those can combine with people eIF-5A2 gene product or fragment but nonrecognition and be incorporated into the antibody of other irrelevant antigen molecule.Among the present invention antibody comprise those can in conjunction with and suppress the proteic molecule of people eIF-5A2, comprise that also those do not influence the antibody of people eIF-5A2 protein function.The present invention also comprise those can with modify or without the people eIF-5A2 gene product bonded antibody of modified forms.

The present invention not only comprises complete mono-clonal or polyclonal antibody, but also comprises having immunocompetent antibody fragment, as Fab ' or (Fab) ₂Fragment; Heavy chain of antibody; Light chain of antibody; Genetically engineered strand Fv molecule; Or chimeric antibody, as have the murine antibody binding specificity but still keep antibody from people's antibody moiety.

Antibody of the present invention can be prepared by the known various technology of those skilled in that art.For example, the people eIF-5A2 gene product of purifying or its have antigenic fragment, can be applied to animal to induce the generation of polyclonal antibody.Similarly, expressing human eIF-5A2 or its have antigenic segmental cell and can be used to immune animal and produce antibody.Antibody of the present invention also can be monoclonal antibody.This type of monoclonal antibody can utilize hybridoma technology to prepare.Antibody of the present invention comprises the antibody that can block people eIF-5A2 function and the antibody that does not influence people eIF-5A2 function.Each antibody-like of the present invention can utilize the fragment or the functional zone of people eIF-5A2 gene product, obtains by the routine immunization technology.These fragments or functional zone can utilize recombinant methods or utilize Peptide synthesizer synthetic.Can come immune animal and produce with the gene product of producing in the prokaryotic cell prokaryocyte (for example E.Coli) with the unmodified form bonded antibody of people eIF-5A2 gene product; With posttranslational modification form bonded antibody (as the albumen or the polypeptide of glycosylation or phosphorylation), can come immune animal and obtain with the gene product that produces in the eukaryotic cell (for example yeast or insect cell).

Based on specific anti-eIF-5A2 antibody, the present invention also provides a kind of method that detects tumour or tumor susceptibility, and it comprises step:

Test kit

The present invention also provides diagnosis eIF-5A2 unusual diagnostic kit.In preference, a kind of test kit comprises one or more probes at eIF-5A2.This test kit also can contain the sealing probe and describe and how to use test kit to detect the illustrative material of eIF-5A2.Test kit also can contain one or more in organizing down: the various markers or the labelled reagent that are used to assist detection probes; The reagent that is used to hybridize (comprising damping fluid, spreading agent in mid-term (metaphase spread), BSA and other closed reagents); Sampling apparatus comprises that fine needle is first-class; And positive and negative hybridization contrast etc.

Compare with the existing additive method that is used for malignant tumour clinical diagnosis and prognosis, superiority of the present invention mainly shows: in view of the closely related property of eIF-5A2 and ovarian cancer, the sensitivity that the inventive method is detecting, accuracy all significantly is better than existing ovarian cancer gene diagnostic method, not only filled up the blind area of detecting, and easy and simple to handle.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold SpringHarbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.

Embodiment

Material

Tumor sample and clone

The primary carcinoma of ovary sample is to obtain by ICR (China, Guangzhou) when operation.Ovarian cancer cell line UACC-1588 and UACC-2727 are the Tissue Culture Core Serivce acquisitions from University of Arizona Comprehensive CancerCenter.

Ovarian cancer cell line OVCAR3 obtains from American type culture collection (ATCC).

Method

Microdissection

The pcr amplification of the DNA of microdissection and micro-dissection is pressed Guan, X.-Y.et al., and Hum.Mol.Genet., 2:1117-1121, the method described in 1993 is carried out.In brief, from the G-band of normal Metaphase Chromosome, separate the 3q26 band that cuts 5 copies.The dna fragmentation of dissecting is handled with topoisomerase I, uses UN1 primer (5 '-CCGACTCGAGNNNNNNATGTGG-3 ') to carry out pcr amplification then.

Synthetic and the library construction of cDNA

(RiboClone cDNA Synthesis System, scheme Promega) make up the cDNA library of causing at random in phage 1GEM4 according to manufacturers.Select for crossbred (hybridization complex), make up test kit (Clontech), prepare random primer synthetic cDNA from OV-4 mRNA with SMARTPCR cDNA Library.

Crossbred is selected

Press Guan, X.-Y.et al., Cancer Res., 56:3446-3450, the method described in 1996 is carried out crossbred and is selected.This method is to use random primer from containing the ovarian cancer OV-4 synthetic cDNA of 3q26 amplification, thereby selects coding region sequence from the 3q26 dna fragmentation of micro-dissection.In brief, the cDNA of 5mg random primer extension is fixed on the nylon membrane of diameter 7mm, and with the PCR product that amplifies from 3q26 district micro-dissection dna fragmentation, at 200 milliliters of hybridization solution (5XSSC, 5X Denhardt ' s solution, 0.1%SDS, 100mg/ml salmon sperm DNA, with 100mg/ml people Cot-1 DNA) in, in 65 ℃ and slightly rock down hybridization spend the night.After tight washing, the micro-dissection DNA of hybridizing is carried out wash-out, and reclaim with PCR.

The cDNA library screening

That PCR is reclaimed, selected dna fragmentation (100ng) is used by random priming (Gibco BRL) ³²P carries out mark, then purifying on Sephadex G50.Probe and 100mg people Cot-1 DNA 65 ℃ of prehybridizations 1 hour, are hybridized with standard method and cDNA library plaque then.

Chromosomal localization

To clone by the BAC that the BLAST database retrieval is selected,, carry out mark by nick-translation with spectrum orange-dUTP (Spectrum-orange-dUTP) (Gibco BRL).Press Guan then, X.-Y.et al., Cancer Res., 56:3446-3450 is described in 1996, with the normal lymphocyte Metaphase Chromosome hybridization of FISH method with probe with the pre-striping (prebanded) of mark.

Southern and Northern engram analysis

To separate with SDS/ phenol/chloroform method from the genomic dna of people's placenta, primary carcinoma of ovary sample and ovarian cancer cell line.Use the EcoRI dna digestion, classification on 1% sepharose then, transfer to nylon membrane (Zeta-probe, Bio-Rad), with ³²The probe at eIF-5A2 and PIK3CA gene of P mark spends the night 42 ℃ of hybridization.Prepare total cell RNA with Trizol/ chloroform method, on 1% agarose/2.2M formaldehyde gel, carry out size fractionation, transfer on the nylon membrane, with ³²The probe at eIF-5A2 and PIK3CA gene of P mark is hybridized.

The preparation of FISH probe and FISH experimental technique

1. random primering (BioPrime DNA Labeling System)

This method uses random primer to come the marker DNA molecule, can produce the label probe that is several times as much as initial DNA amount by labeled reactant.Therefore, this labelling method is specially adapted to only have the mark of a small amount of DNA, as the dna marker of BAC and PAC.In addition, the purity not high (as containing too many RNA) as DNA then is easy to generate more non-special signal, so labelling method is higher to the purity requirement of DNA.Generally can use the random primer labelling test kit of LifeTechnologies company.

(1) 100mg DNA is dissolved in the 24 μ l water, place on ice, add 20 μ l random primer solution (2.5X).Mixed DNA was boiled sex change 5 minutes, place on ice immediately.

(2) add 5 μ l 10XdNTP solution,, add the enzyme solution of 1 μ l more lightly with the thorough mixing of reagent in the centrifuge tube.

(3) behind the mixing, reactant was cultivated 1 hour in 37 ℃, got 2 μ l and do the gel electrophoresis inspection.If the dna probe fragment that is labeled between 200-2000bp, the mark best results.

(4) termination reaction can be by being heated to 75 ℃, and 10 minutes, or add 5 μ l reaction terminating damping fluids.

2. hybridization pre-treatment and in situ hybridization

(1), the karyomit(e) slide is handled in earlier stage

Before the hybridization, will be loaded with last chromosomal slide and carry out the processing of RNA enzyme.On slide, add 200 microlitre RNA enzyme solution (100 μ g/ml are dissolved among the 2XSSC), cover a slide glass, put in 37 ℃ of incubators and digested 30-60 minute, in 2XSSC solution, washed 10 minutes then,, put air drying through 70%, 85%, 100% gradient alcohol dehydration.

(2), karyomit(e) sex change

To prepare and be loaded with metaphase chromosomal slide and put into sex change liquid (70% Formanide, 2XSSC) 75 ℃ of sex change are 2 minutes, through 70%, 85%, 100% gradient alcohol dehydration, air drying.

(3), probe sex change and hybridization

The probe (totally 10 μ l hybridization solutions) in hybridization buffer that adds 50-200mg: 7 μ l hybridization buffers (70% formyl ammonia 2X SSC, 10% T 500), 2 μ l probes, 1 μ l blocking dna (Cot-1 DNA).Hybridization solution behind the mixing is put into 75 ℃ of sex change 5 minutes, change 37 ℃ then over to.Prehybridization 20-30 minute.Probe is dropped on the slide, add cover glass, around sealing with the rubber cement immediately, put into wet box, place to hybridize in 37 ℃ of thermostat containers and spend the night.

3. hybridization aftertreatment and microscopic examination

(1), develops a film

Remove the rubber cement and the cover glass of mounting earlier, slide is placed on 45 ℃ FISH washing lotion I, and (50% formyl ammonia is given a baby a bath on the third day after its birth in 2XSSC) time, each 5-10 minute.Then slide is put among the FISH washing lotion II (4XSSC, 0.05% polysorbas20).It is inferior to give a baby a bath on the third day after its birth, each 2 minutes.Putting into FISH washing lotion III (4XSSC) at last washed 2 minutes.Two steps of back develop a film and all carry out at room temperature.

(2), avidin (Avidin) is handled

Before the processing,, thereby reduce the non-specific hybridization signal earlier with 1% bovine serum albumin (BSA) sealing non-specific antibody binding site.Add 100 microlitre 1%BSA on slide glass, sealing is 30 minutes in 37 ℃, washes in washing lotion III 2 minutes then.Interim preparation avidin and anti-avidin antibody-solutions are dissolved in PNM damping fluid (5 μ g/ml) respectively with avidin and anti-avidin antibody before using.Black out is preserved.The PNM damping fluid is formulated as follows (100ml): with 95ml 0.1M phosphoric acid buffer, pH7,0.1ml NP40,20mg sodium azide and 5g skim-milk, hatched 2 hours in 37 ℃ of water baths of the postposition that is mixed, after treating that milk powder dissolves fully, divide to be filled in the 1.5ml tubule, be stored in-20 ℃, before each the use PNM damping fluid is dissolved, 14,000 rev/mins centrifugal 5 minutes, it is standby to take out supernatant liquor.Add 40 μ l avidins (5 μ g/ml) and on slide, add cover glass, 37 ℃, hatched 20 minutes.Then, slide is put into washing lotion II wash 3 times, wash each 2 minutes among the washing lotion III 1 time.Add the anti-avidin antibody of 40 μ l (5 μ g/ml) subsequently again and on slide, add cover glass, 37 ℃, hatched 20 minutes.Then, slide is put into washing lotion II wash 3 times, wash each 2 minutes among the washing lotion III 1 time.Carry out an avidin at last again and handle, process is the same.

(3). mounting

With the anti-fluid-tight sheet that fades that contains DAPl (0.5-1mg/ml).

Embodiment 1

Microdissection

In this embodiment, in order to determine the candidate oncogene in the 3q26 amplification region, normal Metaphase Chromosome is carried out the 3q26 microdissection.In position in the hybridization, being used for is whole BAC clone as the FISH probe.This BAC clone's title is: RP11-110-0-7.(wherein, RP11 is the library name at this clone place, the-110th, and dish name, the-0th, the X-coordinate at this clone place, the-7th, the ordinate zou at this clone place.) this BAC clone contains the eIF-5A2 gene order.Fluorescence shows that the dna sequence dna and the 3q26 of micro-dissection have specific hybrid (Figure 1B), and the position of hybridization is at karyomit(e) 3q26.2.

Embodiment 2

Crossbred is selected

Select by crossbred, from the DNA of micro-dissection, select the sequence of 3q26 district specifically expressing.By screening 5 * 104 plaques, 31 positive cDNA clones are separated and are checked order.

Sequencing result shows that 4/31 cDNA clone (size is 0.5-2.1kb) has represented a new gene, its open reading frame coding 153 amino acid (Fig. 2).Database retrieval shows that this cDNA and eukaryotic initiation factor 5A (eIF-5A) have significant sequence-specific (82% (126/153) amino acid homogeny) (Fig. 2).The sequence homogeny has comprised and has carried out 8-hydroxyl-2,7, structural domain and lys-50 residue that 10-triamino capric acid is modified, 8-hydroxyl-2 wherein, 7,10-triamino capric acid forms (Kyrpides, N.C.etal. by posttranslational modification, newspaper (Proc.Natl.Acad.Sci.USA) 95:224-228 of institute of American Academy of Sciences, 1998).EIF-5A is the unique known 8-of containing hydroxyl-2,7, the cell protein of 10-triamino capric acid (a kind of non-common amino acid) residue, and 8-hydroxyl-2,7,10-triamino capric acid residue is to form (Park by the posttranslational modification to the lys-50 residue, M.H.et al., Trends Biochem.Sci., 18:475-479,1993).Show, the 8-hydroxyl-2,7 of eIF-5A, 10-triamino capric acidization is crucial for the growth of some tumour generation clone.

New gene of the present invention is named as eukaryotic initiation factor 5A2 (eIF-5A2).The Genbank accession number of eIF-5A2 is AF262027.The nucleotide sequence of eIF-5A2 and aminoacid sequence are shown in SEQ ID NO:1 and 2 respectively.

Embodiment 3

The express spectra of eIF-5A2

In order to determine the express spectra of eIF-5A2 in healthy tissues, use primer based on the eIF-5A2 sequence, normal ovarian tissue and liver, placenta, breast, skin, brain and big intestinal tissue are carried out RT-PCR.The result shows that eIF-5A2 expresses (Fig. 3 C) in all these tissues.

By the BLAST method est database is retrieved, disclosed eIF-5A2 and in people's testis, uterus, lymphocyte and lung tissue, also express.

Embodiment 4

EIF-5A2 is positioned 3q26.2

In order to confirm the chromosomal localization location, isolate the BAC clone who contains the eIF-5A2 sequence with the BLAST method.Carry out Southern blotting (Fig. 3 A) with total length eIF-5A2 cDNA as probe.In addition, use the primer that is arranged in exon (204bp) to carry out pcr amplification ((Fig. 3 B).The both has confirmed that this BAC clone contains eIF-5A2.

Then, use the FISH method, with this BAC clone location and 3q26.2 (Fig. 1 C and 1D).

Embodiment 5

There is amplification in eIF-5A2 in ovarian cancer

Use the Southern blotting, the dna sequence dna amplification situation of eIF-5A2 in the 30 routine primarys carcinoma of ovary is studied.In 15/30 case, detect the eIF-5A2 amplification, and in 4 cases (OV-4, OV-7, OV-13 and OV27), observed high copy amplification (Fig. 4 A, probe are the full-length cDNAs of the eIF-5A2 gene of 1.2kb).In ovarian cancer cell line UACC-1598, also detect the height copy amplification of eIF-5A2, in ovarian cancer cell line UACC-1598, contain the 3q26 amplification (Fig. 4 A) of double minute form.

The expression level of eIF-5A2 is also analyzed with the Northern blotting in 4 primary carcinoma of ovary cases (OV-4, OV-7, OV-13 and OV27) and ovarian cancer cell line UACC-1598, and has all observed eIF-5A2 overexpression (Fig. 4 B).

Embodiment 6

In double minute, there is eIF-5A2

In order to confirm whether double minute contains eIF-5A2, UACC-1598 is hybridized with the FISH method with the BAC clone who contains eIF-5A2 with mid-term.The result shows, BAC clone and all double minute hybridization (Fig. 5 A).Use the FISH method, also in another ovarian cancer cell line (OVCAR3), observe the amplification (Fig. 5 B) of eIF-5A2.According to the inventor's CGH result, defined a minimum overlapping amplicon that is positioned at the 3q26.1-3q26.2 place, and eIF-5A2 just in time is located in this zone (Fig. 5 C).

Embodiment 7

Detect the amplification situation of eIF-5A2 with tissue array technology

In this embodiment, nearly 200 routine ovarian cancer samples are detected, found that about 40% case (76/192) has the eIF-5A2 amplification with organization chip (tissue Microarray) technology.In addition, there is patient's the prognosis of eIF-5A2 gene amplification all relatively poor.

Discuss

In the present invention, from the frequent amplification region of ovarian cancer, isolated a newcomer eIF-5A2 of eIF-5A family.The aminoacid sequence homogeny of eIF-5A2 and eIF-5A is 82%, comprising carrying out 8-hydroxyl-2,7, and structural domain and lys-50 residue that 10-triamino capric acid is modified, 8-hydroxyl-2,7 wherein, 10-triamino capric acid forms by posttranslational modification.This shows that eIF-5A2 is a member of eIF-5A2 family, and may have similar function.

Show that eIF-5A works in translation initiation, yet the disappearance of protein synthesis is not subjected to remarkably influenced in the yeast cell of disappearance eIF-5A.Although the definite function of eIF-5A is not clear, contain 8-hydroxyl-2,7, the necessity of the eIF-5A on cell proliferation of 10-triamino capric acid is fully studied.Show, lack eIF-5A in the complete born of the same parents that cause by having disappearance, can cause the cell growth to be suppressed.Other studies show that, suppress deoxidation 8-hydroxyl-2,7,10-triamino capric acid synthetic enzyme (deoxyhypusinesynthase, DHS) (a kind of at the 8-of eIF-5A hydroxyl-2,7, the enzyme that relates in the 10-triamino capric acidization), can suppress Chinese hamster ovary celI propagation, and growth (Shi, X.-P.et al., the Biochim.Biophys.Acta. of the NIH3T3 cell of containment HeLa cell and v-src conversion, 1310:119-126,1996).People such as Hanauske-Abel hint contains 8-hydroxyl-2,7, the eIF-5A of 10-triamino capric acid may directly influence a related group selection expression of gene in the G1 to S of cell cycle changes in eukaryotic cell, because by suppressing eIF-5A 8-hydroxyl-2,7,10-triamino capric acid modify can make cell cycle arrest the G1-S border phase (Hanauske-Abel et al.Biochim.Biophys.Acta., 1221:15-124).

Recently, people such as Tome report, the accumulation of excessive putrescine and with diamino heptane processing cell and suppress eIF-5A 8-hydroxyl-2,7,10-triamino capric acid is modified, and also is a kind of inducing cell generation mechanism of apoptosis (Tome, M.E.et al., Biochem.J., 328:847-854,1997).

Nearest studies show that, 8-hydroxyl-2,7, and it is serum reactivity that 10-triamino capric acid forms activity, and has significantly increased by 30 times (Chen., Z.P.et al., Cancer Lett., 115:235-241,1997) in the HIH3T3 cell that the Ras oncogene transforms.The dependency that all these research strong hint eIF-5A and cancer take place.

In the present invention, in 15/30 primary carcinoma of ovary and several ovarian cancer cell lines (comprising UACC-1598), detect the eIF-5A2 amplification.And in the primary carcinoma of ovary with 3q26 amplification of all 4 kinds of tests, observe the eIF-5A2 overexpression.In addition, contain the BAC clone of eIF-5A2 and the double minute hybridization among the ovarian cancer cell line UACC-1598.Therefore, based on chromosomal localization, amplification situation and possible and propagation function associated in ovarian cancer, eIF-5A2 is considered to be arranged in the oncogene of inferring of the minimum overlapping amplicon of ovarian cancer 3q26.2.

The 3q26 amplification region may contain more than one important gene (comprising PIK3CA and eIF-5A2), and they are the biological target targets in the ovarian cancer amplification incident.EIF-5A2 is positioned at telomere one side of PIK3CA, and the distance of the genome between it is about 7cM.

All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.

Sequence table＜110〉close Singapore dollar

Cen, letter Chinese bush cherry＜120〉detection method and test kit＜130 of ovarian cancer〉012374＜160〉2＜170〉PatentIn version 3.0＜210〉1＜211〉2246＜212〉DNA＜213〉Homo sapiens＜220〉＜221〉CDS＜222〉(38) .. (499)＜400〉1agttcccacg gaaaaactac catctcccct gcccacc atg gca gac gaa att gat 55

Met?Ala?Asp?Glu?Ile?Asp

1 5ttc?act?act?gga?gat?gcc?ggg?gct?tcc?agc?act?tac?cct?atg?cag?tgc 103Phe?Thr?Thr?Gly?Asp?Ala?Gly?Ala?Ser?Ser?Thr?Tyr?Pro?Met?Gln?Cys

10 15 20tcg?gcc?ttg?cgc?aaa?aac?ggc?ttc?gtg?gtg?ctc?aaa?gga?cga?cca?tgc 151Ser?Ala?Leu?Arg?Lys?Asn?Gly?Phe?Val?Val?Leu?Lys?Gly?Arg?Pro?Cys

25 30 35aaa?ata?gtg?gag?atg?tca?act?tcc?aaa?act?gga?aag?cat?ggt?cat?gcc 199Lys?Ile?Val?Glu?Met?Ser?Thr?Ser?Lys?Thr?Gly?Lys?His?Gly?His?Ala

40 45 50aag?gtt?cac?ctt?gtt?gga?att?gat?att?ttc?acg?ggc?aaa?aaa?tat?gaa 247Lys?Val?His?Leu?Val?Gly?Ile?Asp?Ile?Phe?Thr?Gly?Lys?Lys?Tyr?Glu55 60 65 70gat?att?tgt?cct?tct?act?cac?aac?atg?gat?gtt?cca?aat?att?aag?aga 295Asp?Ile?Cys?Pro?Ser?Thr?His?Asn?Met?Asp?Val?Pro?Asn?Ile?Lys?Arg

75 80 85aat?gat?tat?caa?ctg?ata?tgc?att?caa?gat?ggt?tac?ctt?tcc?ctg?ctg 343Asn?Asp?Tyr?Gln?Leu?Ile?Cys?Ile?Gln?Asp?Gly?Tyr?Leu?Ser?Leu?Leu

90 95 100aca?gaa?act?ggt?gaa?gtt?cgt?gag?gat?ctt?aaa?ctg?cca?gaa?ggt?gaa 391Thr?Glu?Thr?Gly?Glu?Val?Arg?Glu?Asp?Leu?Lys?Leu?Pro?Glu?Gly?Glu

105 110 115cta?ggc?aaa?gaa?ata?gag?gga?aaa?tac?aat?gca?ggt?gaa?gat?gta?cag 439Leu?Gly?Lys?Glu?Ile?Glu?Gly?Lys?Tyr?Asn?Ala?Gly?Glu?Asp?Val?Gln

120 125 130gtg?tct?gtc?atg?tgt?gca?atg?agt?gaa?gaa?tat?gct?gta?gcc?ata?aaa 487Val?Ser?Val?Met?Cys?Ala?Met?Ser?Glu?Glu?Tyr?Ala?Val?Ala?Ile?Lys135 140 145 150ccc?tgc?aaa?taa?acggaaacat?caggcatgaa?cactgtttat?gtctgaatca 539Pro?Cys?Lysactgcaaaaa?taatttggtt?ctaagttgtc?accaaagcta?tagccttcat?aagcaacctc 599atttcttttt?ttaattgttt?tcagattgtg?ctgggttagt?tttgcaagca?attgataatt 659tttaaaaaat?tatcaatatg?tataattttt?tttgaatttt?gtagatatgt?ttcctataat 719attcctgtgg?ttttcagtat?gtcagtccaa?gaaacaaaca?agatagcttc?agcagatgtg 779atttgtctga?gcaaatcatt?cctgtgtttt?agttagatga?taaaccaggg?ttttaaatca 839aacaatgtag?cataaagtgg?tattgaagta?ccatatttaa?gttgaactgc?tctgcattaa 899ttacagattt?aatataaaat?gaactgatta?tatattggaa?ttgttgcact?ttcagcctgt 959gtagggcaaa?cacaaatcct?taaacaaaaa?tcatgttatc?aaaaactgtc?agttattttg 1019gtggccacat?gcaaccatgt?gattactttg?gtcatactat?ttaccaaatt?gttggcaaac 1079ttgatgtaac?cttatatggt?ggttttagtc?ccttcttatg?gttggcagaa?gggcactgaa 1139ctgttgggtg?aaagttagtt?agcaagtaag?attataagga?agacacaaaa?gacagtggca 1199aagagggttg?attaaatcta?taagttttta?tgtgaggact?ttgtaagtca?gcataaaaat 1259gaaaagttgt?ttctcagttg?tttttgcttt?taactttgcc?cccaacgttt?aaagggagtg 1319atctgcttta?catgatacta?tgcaatgctt?gttttccaac?tatgttgaat?aaatagtaat 1379atttatcagt?aaatactcct?ttccaacttc?cttttttttt?tttttttttg?aggcatgaga 1439attgcttgaa?cccgggaagt?gaaggttgcc?gtgagctgag?atcacaccac?tgccataaac 1499atgacaggct?tttggacttt?gtattacctg?tatgttttat?aatggatcat?gcataatttc 1559tcaggagaat?aaaatgagaa?ttcatatata?cgttcatctt?tcaagtcaga?gcaatgagtt 1619gggaaaagag?gtggcatttc?tgatcggata?atggaatact?ctcatttatt?ttatgacatt 1679ctctgtctac?tcagatcata?gtgaaaactg?gaaacaaaaa?aaaaaacagc?ctcttcttgg 1739aaagtgacag?cagaaggtgg?catggagctt?gtgtccttgg?acaacaaatc?tggatatact 1799aggattaatt?atcagaagac?agctcaggcc?aagttttgat?cgttccatac?agtaccttgt 1859ttatctgctt?cttaaagaat?cagccgagac?accataaaag?aaataggctt?tttgtgcctt 1919ttgctgttaa?tgtttaattt?acaaactgtt?ttggtaaatc?tcttaatgta?agtagctatt 1979tgactttgga?attttgcatt?cgaggtatac?tgtcatttct?tgaaatcttt?ttctcgttta 2039gttgctctgt?gggaaatgtg?aggaagccta?agtttgtatt?tgtaaatttc?ttatgccatc 2099ctctagtcaa?attttttttc?attgtttaaa?aatacggaag?tgttccaata?taattttttc 2159ctgtactgga?tggctaggat?tctagagaat?tgattataaa?atattttcaa?tacatcccaa 2219aaaaaaaaaa?aaaaaaaaaa?aaaaaaa 2246<210>2<211>153<212>PRT<213>Homo?sapiens<400>2Met?Ala?Asp?Glu?Ile?Asp?Phe?Thr?Thr?Gly?Asp?Ala?Gly?Ala?Ser?Ser1 5 10 15Thr?Tyr?Pro?Met?Gln?Cys?Ser?Ala?Leu?Arg?Lys?Asn?Gly?Phe?Val?Val

20 25 30Leu?Lys?Gly?Arg?Pro?Cys?Lys?Ile?Val?Glu?Met?Ser?Thr?Ser?Lys?Thr

35 40 45Gly?Lys?His?Gly?His?Ala?Lys?Val?His?Leu?Val?Gly?Ile?Asp?Ile?Phe

50 55 60Thr?Gly?Lys?Lys?Tyr?Glu?Asp?Ile?Cys?Pro?Ser?Thr?His?Asn?Met?Asp65 70 75 80Val?Pro?Asn?Ile?Lys?Arg?Asn?Asp?Tyr?Gln?Leu?Ile?Cys?Ile?Gln?Asp

85 90 95Gly?Tyr?Leu?Ser?Leu?Leu?Thr?Glu?Thr?Gly?Glu?Val?Arg?Glu?Asp?Leu

100 105 110Lys?Leu?Pro?Glu?Gly?Glu?Leu?Gly?Lys?Glu?Ile?Glu?Gly?Lys?Tyr?Asn

115 120 125Ala?Gly?Glu?Asp?Val?Gln?Val?Ser?Val?Met?Cys?Ala?Met?Ser?Glu?Glu

130 135 140Tyr?Ala?Val?Ala?Ile?Lys?Pro?Cys?Lys145 150

Claims

1. A method for detecting human chromosomal abnormalities, characterized in that it comprises steps:

Under the condition that the probe and the target sequence will form a stable hybridization complex, the chromosome sample of the subject is contacted with the composition containing one or more nucleic acid probes, wherein the probes contain full-length eIF-5A2 the nucleotide sequence of a fragment thereof; and

The hybridization complex is detected.

2. The method according to claim 1, wherein the step of detecting the hybrid complex comprises detecting the copy number of the target sequence.

3. The method of claim 1, wherein the detection of the hybrid complex is by detection of a fluorescent marker.

4. The method of claim 1, wherein said chromosomal abnormality is amplification.

5. The method according to claim 1, wherein said full-length eIF-5A2 and its fragments include: DNA, cDNA and antisense DNA.

6. A test kit for detecting cancer, characterized in that it comprises:

A labeled nucleic acid probe, the probe can specifically bind to the nucleotide sequence of human eIF-5A2, and the nucleic acid contains the nucleotide sequence of the full-length eIF-5A2 and its fragments.

7. The kit according to claim 6, further comprising a reference probe specific to the telomeric sequence of chromosome 3.

8. A method of detecting a tumor or tumor susceptibility, characterized in that,

Hybridizing a probe containing the nucleotide sequence of the full-length eIF-5A2 or a fragment thereof with the DNA sample of the individual to be tested; and

Detect whether the number of heterozygotes formed is higher than the normal control,

Whether the number of heterozygotes formed is higher than that of the normal control indicates that the individual suffers from a tumor or the susceptibility of the tumor is higher than that of the normal population.

9. The method of claim 8, wherein said tumor is selected from the group consisting of ovarian cancer, nasopharyngeal cancer, prostate cancer and fallopian tube cancer.

10. A method for detecting tumor or tumor susceptibility, characterized in that it comprises the steps of:

contacting an antibody containing a specific anti-eIF-5A2 protein with a DNA sample of the individual to be tested under conditions suitable for the formation of an antibody complex; and

Detect whether the number of antibody complexes formed is higher than the normal control,

Wherein the number of antibody complexes formed is higher than that of the normal control, it means that the individual has a tumor or the susceptibility of the tumor is higher than that of the normal population.